Mostrar el registro sencillo del ítem

dc.contributor.authorAutorAlegría-Arcos, Melissa
dc.contributor.authorAutorBarbosa, Tábata
dc.contributor.authorAutorSepúlveda, Felipe
dc.contributor.authorAutorCombariza, German
dc.contributor.authorAutorGonzález, Janneth
dc.contributor.authorAutorGil, Carmen
dc.contributor.authorAutorMartínez, Ana
dc.contributor.authorAutorRamírez, David
dc.date.accessionedFecha ingreso2024-09-03T19:17:48Z
dc.date.availableFecha disponible2024-09-03T19:17:48Z
dc.date.issuedFecha publicación2022
dc.identifier.citationReferencia BibliográficaFrontiers in Pharmacology, 13, 11 p.
dc.identifier.issnISSN1663-9812
dc.identifier.uriURLhttp://repositorio.udla.cl/xmlui/handle/udla/1368
dc.identifier.uriURLhttps://www.frontiersin.org/journals/pharmacology
dc.description.abstractResumenThe coronavirus disease 2019 pandemic accelerated drug/vaccine development processes, integrating scientists all over the globe to create therapeutic alternatives against this virus. In this work, we have collected information regarding proteins from SARS-CoV-2 and humans and how these proteins interact. We have also collected information from public databases on protein–drug interactions. We represent this data as networks that allow us to gain insights into protein–protein interactions between both organisms. With the collected data, we have obtained statistical metrics of the networks. This data analysis has allowed us to find relevant information on which proteins and drugs are the most relevant from the network pharmacology perspective. This method not only allows us to focus on viral proteins as the main targets for COVID-19 but also reveals that some human proteins could be also important in drug repurposing campaigns. As a result of the analysis of the SARS-CoV-2–human interactome, we have identified some old drugs, such as disulfiram, auranofin, gefitinib, suloctidil, and bromhexine as potential therapies for the treatment of COVID-19 deciphering their potential complex mechanism of action.
dc.format.extentdc.format.extent11 páginas
dc.format.extentdc.format.extent2.643Mb
dc.format.mimetypedc.format.mimetypePDF
dc.language.isoLenguaje ISOeng
dc.publisherEditorFrontiers Media
dc.rightsDerechosCreative Commons Attribution License (CC BY)
dc.sourceFuentesFrontiers in Pharmacology
dc.subjectPalabras ClavesDrug repurposing
dc.subjectPalabras ClavesNetwork pharmacology
dc.subjectPalabras ClavesProtein–drug interaction network
dc.subjectPalabras ClavesProtein–protein interaction network
dc.subjectPalabras ClavesSARS-CoV-2
dc.subject.lcshdc.subject.lcshCOVID-19 (Enfermedad)
dc.subject.lcshdc.subject.lcshPolypharmacology
dc.titleTítuloNetwork pharmacology reveals multitarget mechanism of action of drugs to be repurposed for COVID-19
dc.typeTipo de DocumentoArtículo
dc.udla.catalogadordc.udla.catalogadorCBM
dc.udla.indexdc.udla.indexWoS
dc.udla.indexdc.udla.indexScience Citation Index Expanded
dc.udla.indexdc.udla.indexScopus
dc.udla.indexdc.udla.indexDOAJ
dc.udla.indexdc.udla.indexBIOSIS
dc.udla.indexdc.udla.indexCAB Abstracts
dc.udla.indexdc.udla.indexEMBASE
dc.identifier.doidc.identifier.doi10.3389/fphar.2022.952192
dc.facultaddc.facultadFacultad de Ingeniería y Negocios


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem